New york city: Nilo Therapeutics, a biotechnology company focused on leveraging neural circuits to restore immune system balance in diseases, has officially launched with a significant $101 million Series A financing. The funding round was led by The Column Group (TCG), DCVC Bio, and Lux Capital, with additional backing from the Gates Foundation and Alexandria Venture Investments. Alongside its launch, Nilo Therapeutics has announced the appointment of Kim Seth, Ph.D., as its new Chief Executive Officer and Board director.

According to BERNAMA News Agency, Nilo Therapeutics was founded by distinguished scientists Charles Zuker, Ph.D. from Columbia University, Ruslan Medzhitov, Ph.D. from Yale University, and Steve Liberles, Ph.D. from Harvard University. The company was established in collaboration with TCG to convert pioneering scientific discoveries in neuro-immunology into innovative therapeutic approaches. Dr. Seth will lead the company alongside Chief Scientific Officer Laurens Kruidenier, Ph.D., as it emerges from its stealth phase and advances into subsequent growth stages. The financing will support the setup of Nilo’s laboratories in New York City, expand its interdisciplinary research and development team, and propel the advancement of its preclinical programs.